Aehr Test Systems Rated Sell Despite FY2027 Rebound: $23 Target Implies 78% Downside

The Quick Take

• Aehr Test Systems carries a Sell rating with a $23 price target, implying approximately 78% downside from its $105.97 price, citing a valuation disconnect from near-term earnings reality.
• The analyst acknowledges a genuine FY2027 revenue rebound driven by wafer-level burn-in demand from silicon carbide and GaN chipmakers, but argues the stock has dramatically overshot fair value.
• At current levels AEHR trades at a premium multiple that assumes flawless execution across multiple fiscal quarters in a sector where product cycles are inherently lumpy.

Aehr Test Systems occupies a specialised niche in semiconductor test equipment, providing wafer-level burn-in and test systems for compound semiconductors—particularly silicon carbide power devices used in electric vehicles and gallium nitride components in power conversion. Revenue tends to be highly concentrated among a small number of large EV and power-device manufacturers, which creates significant quarter-to-quarter lumpiness. After a period of customer inventory destocking that suppressed revenue across two fiscal years, forward bookings data do support a meaningful FY2027 rebound as customers resume capacity investment cycles.

The bear case rests on valuation math rather than business quality. At $105.97, AEHR trades at a significant premium to the discounted value of its FY2027 and FY2028 revenue assumptions even under optimistic scenario modelling. The analyst's $23 price target derives from a sum-of-parts that assumes normalised margins on FY2027 revenues with no incremental multiple expansion—arguing the stock requires perfect execution and sustained customer concentration to justify even a fraction of its current price. A single large customer delaying a wafer-level test tool order by one quarter, which has occurred repeatedly in AEHR's history, would collapse the premium multiple rapidly.

For investors currently long AEHR, the risk-management question is whether to treat the rebound thesis as a near-term trading opportunity to harvest gains or as a longer-duration position. The compound semiconductor test market is structurally growing as EV and power-electronics manufacturing scales globally, and Aehr's proprietary WaferPak contactors provide genuine switching costs. However, at a 78% implied downside to the analyst's target, current holders are betting that the market will sustain a multi-year premium throughout an uncertain customer ramp cycle—a high bar for what remains a small-cap, concentration-heavy business.

Synthesized from 1 source.